- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04489849
Apixaban for Prevention of Post-angioplasty Thrombosis of Hemodialysis Vascular Access
Taiwan was among the countries with high prevalence of end stage renal disease (ESRD), and more than 90% of ESRD patients in Taiwan received hemodialysis. Thrombosis are the most common complications of hemodialysis vascular access, with an annual incidence of 30-65% for dialysis grafts. Although endovascular thrombectomy is effective and convenient, the recurrence rate was high, nearly 50% in three months.
The mechanisms of dialysis vascular access thrombosis were multi-factorial, including flow stasis, endothelial injury and hypercoagulability. Our recent study showed that 63% of patients with early thrombosis after angioplasty had at least one thrombophilic factor. Nonetheless, no antithrombotic regimen has been validated to be effective for prevention of thrombosis, either primary or secondary prevention. Novel oral anticoagulants (NOACs) have shown comparable efficacy as VKA with significant decrease in major bleeding. Furthermore, NOACs have the advantage of rapid onset without the need for titration, which should be more effective in the critical period early after thrombectomy. NOAC have almost replaced the role of VKA for the prevention of stroke in patients with atrial fibrillation. They also replaced oral and parenteral anticoagulants in the treatment and prevention of deep vein thrombosis. Among the 4 available NOACs today, only apixaban had received approval by the US Food and Drug Administration (FDA) to be used in patients with ESRD for stroke prevention in atrial fibrillation.
In consideration of the trade-off between thrombotic and bleeding risk, we aimed at secondary prevention for patients with a thrombosis event after a successful thrombectomy procedure. Apixaban would be used because it was approved by FDA for the use of hemodialysis patients, with a risk of major bleeding of 5% for 3 months. Furthermore, considering the ethnic (Asia population) and clinical (ESRD and high bleeding risk) background of our target population, 2.5 mg twice daily dose was chosen in this study to minimize the bleeding risk. This study is a multi-center, prospective, open-labeled, randomized trial with blinded evaluation of all outcomes (PROBE design). We anticipated to enroll 150 patients, with 1:1 randomization to apixaban and control group (no antithrombotic agent). The duration of therapy will be 3 months and the primary outcome is the time to recurrent thrombotic event. Secondary outcomes included frequency of thrombosis, repeat interventions, and bleeding events. We hypothesized that apixaban could prolong the thrombosis-free interval after a successful thrombectomy procedure of hemodialysis vascular access.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Tsung-Yu Ko, MD
- Phone Number: 03-5326151
- Email: sonicwind1022@gmail.com
Study Contact Backup
- Name: TsungYu Ko, MD
- Phone Number: 03-5326151
- Email: sonicwind1022@gmail.com
Study Locations
-
-
-
Hsinchu, Taiwan, 300
- Recruiting
- National Taiwan University Hospital Hsinchu Branch
-
Contact:
- NienChu Kui
- Email: hch01215@hch.gov.tw
-
Hsinchu, Taiwan, 300
- Recruiting
- National Taiwan University Hospital,HsinChu branch
-
Contact:
- NienChu Kui
- Email: hch01215@hch.gov.tw
-
Sub-Investigator:
- Tsung-Yu Ko, MD
-
Principal Investigator:
- Chih-Cheng Wu, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 20-99 years old
- End stage renal disease, patients on maintenance hemodialysis for at least one month
- Dialysis vascular access thrombosis, documented by angiograph, and thrombosis was salvaged by endovascular or surgical procedures successfully
Exclusion Criteria:
- History of intracranial hemorrhage
- Major bleeding in recent 3 months, which defined as Bleeding Academic Research Consortium (BARC) 2 criteria
- Concomitant use of dual antiplatelet agent (aspirin and clopidogrel)
- Concomitant use of ticagrelor
- Concomitant use of warfarin
- Planned to receive surgery in recent 3 months
- Planned to receive coronary stents in recent 3 months
- Hemoglobin < 7.0 g/dL or Platelet count < 80 K/uL
- Moderate or severe liver dysfunction, defined as Child-Pugh score > 6
- Patient received bioprosthetic or mechanical heart valve
- Cannot signed informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Apixaban
Apixaban 2.5mg BID
|
apixaban 2.5mg BID for 3 months in experimental group
|
Active Comparator: Control
Other treatment except oral anticoagulant
|
Medication other than anticoagulation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Thrombosis rate
Time Frame: 3 months
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency of thrombosis
Time Frame: 3 months
|
3 months
|
|
Frequency of angioplasty for vascular access
Time Frame: 3 months
|
3 months
|
|
Major bleeding event
Time Frame: 3 months
|
Major bleeding according to BARC2 criteria
|
3 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 108-029-F
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hemodialysis Access Failure
-
National Taiwan University Hospital Hsin-Chu BranchCompletedHemodialysis Access Failure
-
Brigham and Women's HospitalNot yet recruitingHemodialysis Access FailureUnited States
-
Egyptian Biomedical Research NetworkCompletedHemodialysis Access FailureEgypt
-
Assiut UniversityUnknownHemodialysis Access Failure
-
The University of QueenslandAustralasian Kidney Trials NetworkActive, not recruitingVascular Access Complication | Hemodialysis Access Failure (Disorder)Netherlands, Switzerland, Canada, France, United Kingdom, Australia, Malaysia
-
National Taiwan University Hospital Hsin-Chu BranchUnknownHemodialysis Access Failure | Blood Pressure | Dialysis Access MalfunctionTaiwan
-
National Taipei University of Nursing and Health...UnknownHemodialysis Access Failure | Renal Dialysis | Integrative MedicineTaiwan
-
Shanghai Zhongshan HospitalUnknownHemodialysis Access Failure | Hemodialysis ComplicationChina
-
National Taiwan University Hospital Hsin-Chu BranchUnknownHemodialysis Access Failure (Disorder) | Stent-Graft Restenosis | Arteriovenous Graft | Drug-coated BalloonTaiwan
-
Maastricht University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentRecruitingHemodialysis Access Failure | Dialysis Access Malfunction | Vascular Access Malfunction | Hemodialysis Fistula ThrombosisNetherlands
Clinical Trials on Apixaban 2.5 MG
-
Assistance Publique - Hôpitaux de ParisBristol-Myers SquibbActive, not recruitingCancer-associated ThrombosisFrance, Spain, Netherlands, Belgium, Austria, Greece, Switzerland, Canada, Italy, Poland, United Kingdom
-
University Hospital, GenevaSunnybrook Health Sciences CentreNot yet recruitingDeep Vein Thrombosis
-
Instituto de Investigacion Sanitaria La FeBristol-Myers SquibbTerminated
-
Artivion Inc.Duke Clinical Research InstituteTerminatedAortic Valve Stenosis | Aortic Valve Disease | Aortic Valve FailureUnited States
-
Brazilian Clinical Research InstituteHospital Israelita Albert Einstein; Hospital Moinhos de Vento; Hospital do Coracao and other collaboratorsTerminatedCovid19 | ThrombosisBrazil
-
Thomas L. OrtelNational Heart, Lung, and Blood Institute (NHLBI)Completed
-
Brigham and Women's HospitalActive, not recruitingDeep Vein Thrombosis | Venous Thromboembolism | Pulmonary EmbolismUnited States
-
Janssen Research & Development, LLCCompletedVTE Prophylaxis With Anticoagulation After Total Knee Replacement SurgeryBelgium, Italy, Malaysia, Latvia, Spain, Turkey, Bulgaria, United States, Lithuania, Russian Federation, Ukraine, Japan, Argentina, Brazil, Canada, Poland
-
Duke UniversityPatient-Centered Outcomes Research InstituteTerminatedVenous ThromboembolismUnited States
-
University Hospital Inselspital, BerneCentre Hospitalier Universitaire VaudoisRecruitingLiver CirrhosisSwitzerland